Genor Biopharma Holdings (HKG:6998) proposed to remove its auditor PricewaterhouseCoopers due to disagreements over audit documentation and financial reporting period for publishing results, according to a Tuesday filing with the Hong Kong bourse.
The company also proposed the appointment of Ernst & Young as the new auditor, subject to shareholder approval at an upcoming extraordinary general meeting on Feb. 19.
The pharmaceutical company's shares were almost 2% higher in recent trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.